187724-88-5

Basic information

• Product Name: 1H-Pyrrole-3-carboxylic acid, 2-aMino-5-(4-nitrophenyl)-, ethyl ester
• Synonyms: 1H-Pyrrole-3-carboxylic acid, 2-aMino-5-(4-nitrophenyl)-, ethyl ester;Ethyl 2-amino-5-(4-nitrophenyl)-1H-pyrrole-3-carboxylate
• CAS NO: 187724-88-5
• Molecular Formula: C₁₃H₁₃N₃O₄
• Molecular Weight: 275.26002
• Mol File: 187724-88-5.mol

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 1H-Pyrrole-3-carboxylic acid, 2-aMino-5-(4-nitrophenyl)-, ethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-Pyrrole-3-carboxylic acid, 2-aMino-5-(4-nitrophenyl)-, ethyl ester(187724-88-5)
• EPA Substance Registry System: 1H-Pyrrole-3-carboxylic acid, 2-aMino-5-(4-nitrophenyl)-, ethyl ester(187724-88-5)

Safety Data

• Hazardous Substances Data: 187724-88-5(Hazardous Substances Data)

Usage

Molecular Weight

254.26 g/mol

Structure

A pyrrole ring with a carboxylic acid group at position 3, an amino group at position 2, and a 4-nitrophenyl group at position 5, with an ethyl ester group attached to the carboxylic acid.

Class

Pyrrole compounds

Derivative

Ethyl ester derivative of 2-amino-5-(4-nitrophenyl)-1H-pyrrole-3-carboxylic acid

Usage

Often used in laboratory research

Potential Applications

Pharmaceuticals and biochemistry

Biological Activities

Diverse range of biological activities

Therapeutic Properties

Potential therapeutic properties, but further research is required to fully understand its potential applications and effects.

Upstream product

• 57508-48-2 carbethoxyacetamidine hydrochloride 
• 99-81-0 4-Nitrophenacyl bromide 

Relevant articles and documents

MULTI-FUNCTIONAL SMALL MOLECULES AS ANTI-PROLIFERATIVE AGENTS

The present invention relates to the compositions, methods, and applications of a novel approach to selective inhibition of several cellular or molecular targets with a single small molecule. More specifically, the present invention relates to multi-functional small molecules wherein one functionality is capable of inhibiting histone deacetylases (HDAC) and the other functionality is capable of inhibiting a different cellular or molecular pathway involved in aberrant cell proliferation, differentiation or survival.

FUSED BICYCLIC PYRIMIDINES AS PTK INHIBITORS CONTAINING A ZINC BINDING MOIETY

The present invention relates to fused bicyclic pyrimidine containing zinc- binding moiety based derivatives that have unique properties as protein tyrosine kinase (PTK) inhibitors and their use in the treatment of PTK related diseases and disorders such as cancer. The said derivatives may further act as HDAC inhibitors.

Pyrrolopyrimidines and processes for their preparation

PCT No. PCT/EP97/00127 Sec. 371 Date Jul. 22, 1998 Sec. 102(e) Date Jul. 22, 1998 PCT Filed Jan. 13, 1997 PCT Pub. No. WO97/27199 PCT Pub. Date Jul. 31, 1997There are described compounds of formula I wherein R1 and R2 are as defined in the description, Q is heterocyclyl boned via a ring nitrogen atom and having the formula IA wherein R3 and R4 and m and n are as defined in the description, the ring marked A is a heterocyclyl having 5 to 9 ring atoms and having at least one saturated bond, it being possible for a further ring hetero atom selected from O and S to be present in addition to the bonding nitrogen atom, the ring system marked B is a free or benzo-, thieno-, furo-, pyrrolo- or dihydropyrrolo-fused carbocyclic ring having from 5 to 9 carbon atoms that is fused to the ring A and may be unsaturated, partially saturated or fully saturated, and the bond marked by a parallel dotted line between the ring systems marked A and B is either a single bond or a double bond, and a salt thereof where at least one salt-forming group is present. The compounds are inhibitors of protein kinases and have, for example, antitumour activity.

Pyrrolopyrimidines and processes for the preparation thereof

PCT No. PCT/EP96/02728 Sec. 371 Date Jan. 26, 1998 Sec. 102(e) Date Jan. 26, 1998 PCT Filed Jun. 24, 1996 PCT Pub. No. WO97/02266 PCT Pub. Date Jan. 23, 1997Described are 7H-pyrrolo[2,3-d]pyrimidine derivatives of formula I wherein the symbols are as defined in claim 1. Those compounds inhibit tyrosine protein kinase and can be used in the treatment of hyperproliferative diseases, for example tumour diseases.